PROTAC Bcl-xL degrader-1

Cat. No.: HY-131188

Molecular Formula: $C_{76}H_{96}ClF_3N_{10}O_{11}S_3$

Molecular Weight: 1514.28

Target: PROTACs; Bcl-2 Family

Pathway: PROTAC; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC_{50} values of 62 nM and 8.5 μM, respectively[1].

IC_{50} & Target	cIAP1	Bcl-xL

In Vitro

PROTAC Bcl-xL degrader-1 (Compound 8a; 0.01-3 μM; 16 hours; MyLa 1929 cells) treatment potently and dose-dependently induces BCL-XL degradation in MyLa 1929 cells[1].

PROTAC Bcl-xL degrader-1 (Compound 8a) is able to induce remarkable BCL-XL degradation in a dose-dependent manner across all tested cell lines (A549, MDA-MB-231, SW620, MeWo, SK-MEL28, and CHL-1 cell lines), suggesting the broad application across cancer types[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MyLa 1929 cells
Concentration:	0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM
Incubation Time:	16 hours
Result:	Potently and dose-dependently induced BCL-XL degradation in MyLa 1929 cells.

REFERENCES

[1]. Xuan Zhang, et al. Discovery of IAP-recruiting BCL-X L PROTACs as Potent Degraders Across Multiple Cancer Cell Lines. Eur J Med Chem. 2020 Aug 1;199:112397.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA